Recent Research Analysts’ Ratings Changes for STADA Arzneimittel (SAZ)

STADA Arzneimittel (ETR: SAZ) recently received a number of ratings updates from brokerages and research firms:

  • 12/26/2017 – STADA Arzneimittel was given a new €89.00 ($105.95) price target on by analysts at Independent Research GmbH. They now have a “neutral” rating on the stock.
  • 12/26/2017 – STADA Arzneimittel was given a new €66.25 ($78.87) price target on by analysts at Commerzbank Ag. They now have a “sell” rating on the stock.
  • 12/26/2017 – STADA Arzneimittel was given a new €74.40 ($88.57) price target on by analysts at Nord/LB. They now have a “sell” rating on the stock.
  • 12/20/2017 – STADA Arzneimittel was given a new €74.40 ($88.57) price target on by analysts at Nord/LB. They now have a “sell” rating on the stock.
  • 12/20/2017 – STADA Arzneimittel was given a new €66.25 ($78.87) price target on by analysts at Commerzbank Ag. They now have a “sell” rating on the stock.
  • 12/20/2017 – STADA Arzneimittel was given a new €89.00 ($105.95) price target on by analysts at Independent Research GmbH. They now have a “neutral” rating on the stock.
  • 12/20/2017 – STADA Arzneimittel was given a new €74.40 ($88.57) price target on by analysts at Warburg Research. They now have a “sell” rating on the stock.
  • 11/29/2017 – STADA Arzneimittel was given a new €74.40 ($88.57) price target on by analysts at Nord/LB. They now have a “sell” rating on the stock.
  • 11/10/2017 – STADA Arzneimittel was given a new €74.40 ($88.57) price target on by analysts at S&P Global. They now have a “sell” rating on the stock.
  • 11/10/2017 – STADA Arzneimittel was given a new €82.00 ($97.62) price target on by analysts at Independent Research GmbH. They now have a “neutral” rating on the stock.
  • 11/10/2017 – STADA Arzneimittel was given a new €74.40 ($88.57) price target on by analysts at Warburg Research. They now have a “sell” rating on the stock.

STADA Arzneimittel AG (SAZ) traded up €0.28 ($0.33) during trading hours on Tuesday, reaching €88.92 ($105.86). 10,198 shares of the company’s stock were exchanged, compared to its average volume of 56,910. The stock has a market capitalization of $5,550.00 and a P/E ratio of 58.50. STADA Arzneimittel AG has a 12 month low of €46.31 ($55.13) and a 12 month high of €89.76 ($106.86).

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit